Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1,45%
1 082,80
+15,44
+1,45%
—1 067,361 073,631 085,941 073,63——
SIXC
Communications
SIXC
Communications
SIXC
+0,05%
603,77
+0,29
+0,05%
—603,48603,48606,47601,43——
SIXE
Energy
SIXE
Energy
SIXE
-2,71%
1 211,19
-33,74
-2,71%
—1 244,931 238,101 246,591 210,94——
SIXI
Industrials
SIXI
Industrials
SIXI
+1,48%
1 755,99
+25,61
+1,48%
—1 730,381 737,301 760,621 737,30——
SIXM
Financials
SIXM
Financials
SIXM
-0,15%
638,51
-0,96
-0,15%
—639,47639,46643,01636,91——
SIXR
Staples
SIXR
Staples
SIXR
-1,40%
842,96
-11,99
-1,40%
—854,95854,97855,66842,13——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,33%
219,28
+0,72
+0,33%
—218,56218,56220,16218,53——
SIXT
Technology
SIXT
Technology
SIXT
+2,66%
3 728,35
+96,76
+2,66%
—3 631,593 687,983 744,373 675,71——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,03%
915,48
-0,29
-0,03%
—915,77917,87921,16915,35——
SIXV
Health care
SIXV
Health care
SIXV
-1,02%
1 497,36
-15,45
-1,02%
—1 512,811 514,561 514,951 497,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,21%
2 413,17
+4,96
+0,21%
—2 408,212 418,112 427,232 398,16——
Q1 2026 earnings • released • Revenue beat +291,75%
See results
ABVX:EPA
Abivax SA
109,80 €
-4,60%
(-5,30) 1D
26-май, 17:35:28 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
114,50 €
High
118,00 €
Low
104,00 €
Mkt. cap
9,05 млд
Avg. vol.
121,16 миң
Volume
350,72 миң
52-wk high
132,00 €
52-wk low
5,06 €
EPS
-4,83 €
Shares outstanding
79,69 млн
No. of employees
69
News stories
From sources across the web
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees69
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com
Last report
2026-ж., 22-май
Fiscal period
Q1 2026
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
1,34 млн / 343,08 миң
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
1,05 млн
639,00 миң
1,91 млн
1,34 млн
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
38,64 млн
55,42 млн
44,40 млн
49,54 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,94 млн
27,34 млн
27,69 млн
8,03 млн
Operating expense
47,54 млн
81,35 млн
73,56 млн
57,57 млн
Total operating expenses
47,54 млн
81,35 млн
73,56 млн
57,57 млн
Operating income
-46,50 млн
-80,71 млн
-71,65 млн
-56,23 млн
Other non operating income
2,66 млн
-74,20 млн
-4,96 млн
12,76 млн
EBT including unusual items
-48,41 млн
-153,36 млн
-76,11 млн
-48,24 млн
EBT excluding unusual items
-48,41 млн
-153,36 млн
-80,84 млн
-48,24 млн
Income tax expense
-
-
5,85 млн
228,00 миң
Effective tax rate
-
-
-7,68%
-0,47%
Other operating expenses
-46,00 миң
-1,40 млн
1,47 млн
-
Net income
-48,41 млн
-153,36 млн
-81,96 млн
-48,47 млн
Net profit margin
-4 624,07%
-23 999,69%
-4 282,13%
-3 606,25%
Earnings per share
-
-
-
-
Interest and investment income
190,00 миң
3,36 млн
1,19 млн
-
Interest expense
-3,52 млн
-4,21 млн
-15,27 млн
-4,77 млн
Net interest expenses
-3,33 млн
-852,00 миң
-14,08 млн
-4,77 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-46,47 млн
-80,63 млн
-70,76 млн
-55,86 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer